This site requires JavaScript to render the code.

Need to know how to enable JavaScript? Go here.

CEO of Self-screen, prof.dr. Chris Meijer has presented the science behind the QIAsure Methylation test on the Interactive Thematic Workshops “From recognition to treatment”, held on 6 and 7 April 2018 in Poznan, Polen. The Workshops were organized by the Polish Society of Colposcopy and Cervical Pathophysiology. Chairman of the symposium was Professor dr hab. Witold Kędzia.
The presentation of Chris Meijer, “Methylation of selected genes as a marker of cervical carcinogenesis”, introduced the innovative new science behind the QIAsure methylation test to an audience of more than 300 clinicians.
The QIAsure Methylation Test is a real-time PCR-based molecular assay to distinguish women with cervical (pre)cancer. The test specifically detects women with a cancer-like methylation profile that have a short term high risk for progression to cervical cancer. With that it can be used as triage test for women with a positive HPV DNA test or for women with ASC-US cytology to identify those women that need to be referred for a colposcopy.
For information see: